Exponent price target lowered to $100 from $120 at Truist

Truist lowered the firm’s price target on Exponent (EXPO) to $100 from $120 and keeps a Buy rating on the shares. The gutting of regulators could be a headwind to growth, but the Trump Administration’s increasing scrutiny around chemicals in food is an example of a new opportunity that can fill holes if proactive engagements decline, the analyst tells investors in a research note. Tariffs causing companies to construct new supply chains can also be a long-term catalyst, the firm adds.